Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Share:
Related JNJ
No Tears In Johnson & Johnson
Baird Says Buy Cooper Companies At Current Levels
Q2 2016 Update For The R.I.P. Portfolio: Playing Catch Up (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

DateFirmActionFromTo
Jun 2016JefferiesMaintainsHold
May 2016Standpoint ResearchInitiates Coverage onSell
May 2016BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!